Recombinant multi-species ZNF449 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ZNF449 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a nuclear protein that likely functions as a transcription factor. The protein includes an N-terminal SCAN domain, and seven C2H2-type zinc finger motifs. [provided by RefSeq, May 2010]
The Alternative Names of target: 9530049C15Rik,ZNF449,ZSCAN19,Zfp449,Zinc finger and SCAN domain-containing protein 19,Zinc finger protein 449

Target products collectionGo to ZNF449 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE1604-Ag-1/ GM-Tg-hg-SE1604-Ag-2 Human ZNF449 protein Human
GM-Tg-rg-SE1604-Ag-1/ GM-Tg-rg-SE1604-Ag-2 Rat ZNF449 protein Rat
GM-Tg-mg-SE1604-Ag-1/ GM-Tg-mg-SE1604-Ag-2 Mouse ZNF449 protein Mouse
GM-Tg-cynog-SE1604-Ag-1/ GM-Tg-cynog-SE1604-Ag-2 Cynomolgus/Rhesus macaque ZNF449 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE1604-Ag-1/ GM-Tg-felg-SE1604-Ag-2 Feline ZNF449 protein Feline
GM-Tg-cang-SE1604-Ag-1/ GM-Tg-cang-SE1604-Ag-2 Canine ZNF449 protein Canine
GM-Tg-bovg-SE1604-Ag-1/ GM-Tg-bovg-SE1604-Ag-2 Bovine ZNF449 protein Bovine
GM-Tg-equg-SE1604-Ag-1/ GM-Tg-equg-SE1604-Ag-2 Equine ZNF449 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE1604-Ag-1/ GM-Tg-hg-SE1604-Ag-2; GM-Tg-rg-SE1604-Ag-1/ GM-Tg-rg-SE1604-Ag-2;
GM-Tg-mg-SE1604-Ag-1/ GM-Tg-mg-SE1604-Ag-2; GM-Tg-cynog-SE1604-Ag-1/ GM-Tg-cynog-SE1604-Ag-2;
GM-Tg-felg-SE1604-Ag-1/ GM-Tg-felg-SE1604-Ag-2; GM-Tg-cang-SE1604-Ag-1/ GM-Tg-cang-SE1604-Ag-2;
GM-Tg-bovg-SE1604-Ag-1/ GM-Tg-bovg-SE1604-Ag-2; GM-Tg-equg-SE1604-Ag-1/ GM-Tg-equg-SE1604-Ag-2
Products Name ZNF449 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name ZNF449
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ZNF449 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.